RPRX 8-K 2026-11-04
Royalty Pharma plc (RPRX) 8-K dated 2026-11-04 — accession 0001802768-26-000026.
Royalty Pharma plc (RPRX) is a biotechnology company listed on US.
RPRX to acquire platform ($350M)
This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported RPRX revenue for 2025-12-31 was $2.38B. Net income was $770.9M. Revenue was up 5.1% from 2024-12-31 to 2025-12-31. RPRX currently screens at market cap $20.45B and trailing P/E 35.5.
Not investment advice. The RPRX SEC hub lists recent forms. The stock page is the research view.
- Guidance
- full year 2026 guidance: Portfolio Receipts expected to be $3,500 million to $3,550 million
- Deal
- $350M
Why it matters
- full year 2026 guidance: Portfolio Receipts expected to be $3,500 million to $3,550 million
- Transaction value about $350M
- Royalty Pharma delivered excellent third quarter 2026 results and we again raised our financial guidance,…